2,3,5-Trimethoxyamphetamine
2,3,5-Trimethoxyamphetamine, also known as TMA-4, is a psychedelic drug of the phenethylamine and amphetamine families. It is one of the possible positional isomers of trimethoxyamphetamine and is a positional isomer of 3,4,5-trimethoxyamphetamine.
Use and effects
In his book PiHKAL and other publications, Alexander Shulgin lists 2,3,5-TMA's dose as greater than 80mg orally and its duration as perhaps or about 6hours. Based on limited testing, it produced threshold effects including much introspection among others, along with no subjective physical symptoms. The drug at 80mg was described as comparable to 50μg LSD or 120mg TMA and as being roughly 4-fold as potent as mescaline. Per Shulgin, more testing is needed to fully characterize the drug in humans.
Pharmacology
Pharmacodynamics
2,3,5-TMA shows affinity for serotonin receptors. The drug substitutes for DOM in rodent drug discrimination tests.
Chemistry
Synthesis
The chemical synthesis of 2,3,5-TMA has been described.
History
2,3,5-TMA was first described in the scientific literature by Alexander Shulgin in 1966. Subsequently, it was described in greater detail by Shulgin in his 1991 book PiHKAL.
Canada
2,3,5-TMA is a controlled substance in Canada under phenethylamine blanket-ban language.
As a positional isomer of 3,4,5-trimethoxyamphetamine, 2,3,5-TMA is a Schedule I controlled substance in the United States.